Colorectal Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
PRKCDBP is a proapoptotic tumor suppressor which is commonly altered in colorectal cancer by promoter hypermethylation, and its gene transcription is directly activated by NF-κB in response to TNFα.
|
21980136 |
2011 |
Colorectal Carcinoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
These results provide a basis for future clinical studies to validate SRBC hypermethylation as a predictive marker for oxaliplatin resistance in colorectal cancer.
|
24273214 |
2014 |
Malignant neoplasm of lung
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers.
|
11691816 |
2001 |
Malignant neoplasm of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Normal hSRBC protein expression was detected in only 18% of primary NSCLCs (N=93) by immunostaining and a significant association between loss of protein expression and methylation was found. hSRBC re-expression was observed after treatment of lung cancer cells with the demethylating agent 5-aza-2'-deoxycytidine.
|
15940253 |
2005 |
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker
|
disease |
BEFREE |
PRKCDBP is a proapoptotic tumor suppressor which is commonly altered in colorectal cancer by promoter hypermethylation, and its gene transcription is directly activated by NF-κB in response to TNFα.
|
21980136 |
2011 |
Malignant neoplasm of colon and/or rectum
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
These results provide a basis for future clinical studies to validate SRBC hypermethylation as a predictive marker for oxaliplatin resistance in colorectal cancer.
|
24273214 |
2014 |
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Gene expression profiling identified PRKCDBP in the 11p15 region to be significantly downregulated in both BCBM and primary BC with brain relapse compared to primary tumors without relapse or bone metastasis (fdr<0.05). qRT-PCR confirmed these results and methylation was shown to be a common way to silence this gene.
|
23118876 |
2012 |
Malignant neoplasm of endometrium
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphism of PRKCDBP is associated with an increased risk of endometrial cancer.
|
23020606 |
2012 |
Ulcerative Colitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To explore the potential of PRKCDBP as a diagnostic or prognostic marker for inflammatory bowel disease, the possible correlation between its expression status and TNF-α signaling was evaluated in ulcerative colitis (UC) patients, both pre- and post-infliximab (IFX) therapy.
|
25052149 |
2014 |
Depressive disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our aim was to study SDPR, PRKCDBP, CRY1 and CRY2 genetic variants in depressive disorders.
|
27721187 |
2017 |
Hepatitis C
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Cavin-1, cavin-2, and cavin-3 proteins and their gene expression were examined using immunohistochemistry (IHC), Western blotting, and laser capture microdissection (LCM)-polymerase chain reaction (PCR) during progression of cirrhosis caused by hepatitis C. According to the perfusion, fixation methods were designed to reevaluate the precise ultrastructural localizations and changes of cavin-1 and cavin-2 expression on liver sinusoidal endothelial cells (LSECs) facing the sinusoidal blood flow.
|
26086560 |
2015 |
Liver Cirrhosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Cavin-1, cavin-2, and cavin-3 proteins and their gene expression were examined using immunohistochemistry (IHC), Western blotting, and laser capture microdissection (LCM)-polymerase chain reaction (PCR) during progression of cirrhosis caused by hepatitis C. According to the perfusion, fixation methods were designed to reevaluate the precise ultrastructural localizations and changes of cavin-1 and cavin-2 expression on liver sinusoidal endothelial cells (LSECs) facing the sinusoidal blood flow.
|
26086560 |
2015 |
Malignant neoplasm of stomach
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses.
|
18059034 |
2008 |
Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our study, a low methylation frequency of SCNN1A, PRKCDBP and KRT19 is significantly associated with favorable outcome in neuroblastoma.
|
21314941 |
2011 |
Unipolar Depression
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CRY2 and PRKCDBP variants may be risk factors of major depressive disorder and provide information for diagnosis.
|
27721187 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma.
|
30894682 |
2019 |
Secondary malignant neoplasm of bone
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Gene expression profiling identified PRKCDBP in the 11p15 region to be significantly downregulated in both BCBM and primary BC with brain relapse compared to primary tumors without relapse or bone metastasis (fdr<0.05). qRT-PCR confirmed these results and methylation was shown to be a common way to silence this gene.
|
23118876 |
2012 |
Metastatic malignant neoplasm to brain
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.
|
23118876 |
2012 |
Carcinoma breast stage IV
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.
|
23118876 |
2012 |
Endometrial Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphism of PRKCDBP is associated with an increased risk of endometrial cancer.
|
23020606 |
2012 |
Metabolic Syndrome X
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we wanted to investigate whether variants of the core circadian clock genes, cryptochrome circadian clocks 1 and 2 (CRY1 and CRY2), or those of protein kinase C, delta binding protein (PRKCDBP), which regulate the interactions and abundance of dimers of the period and cryptochrome proteins, are associated with metabolic syndrome or its components.
|
25391456 |
2015 |
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Gene expression profiling identified PRKCDBP in the 11p15 region to be significantly downregulated in both BCBM and primary BC with brain relapse compared to primary tumors without relapse or bone metastasis (fdr<0.05). qRT-PCR confirmed these results and methylation was shown to be a common way to silence this gene.
|
23118876 |
2012 |
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Normal hSRBC protein expression was detected in only 18% of primary NSCLCs (N=93) by immunostaining and a significant association between loss of protein expression and methylation was found. hSRBC re-expression was observed after treatment of lung cancer cells with the demethylating agent 5-aza-2'-deoxycytidine.
|
15940253 |
2005 |
Stomach Carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses.
|
18059034 |
2008 |
Central neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our study, a low methylation frequency of SCNN1A, PRKCDBP and KRT19 is significantly associated with favorable outcome in neuroblastoma.
|
21314941 |
2011 |